子宫内膜癌多药耐药基因1产物表达及其临床意义

目的：探讨子宫内膜癌多药耐药（ｍｕｌｔｉｄｒｕｇｒｅｓｉｓｔａｎｃｅ１，ＭＤＲ１）基因１产物Ｐ糖蛋白（Ｐｇｐ）表达与子宫内膜癌ＭＤＲ的关系。方法：用ＳＰ免疫组化法测定４０例子宫内膜癌，１０例子宫内膜增殖症和１０例正常子宫内膜组织Ｐｇｐ表达，并与ＰＲ受体、细胞分级和临床分期等预后因素进行相关分析。结果：（１）上述所有组织均有Ｐｇｐ表达，其中子宫内膜癌Ｐｇｐ强阳性表达率较正常子宫内膜组织高，差异有显著性；与子宫内膜增殖症比较，二者差异无显著性。（２）Ｐｇｐ强阳性表达与子宫内膜癌临床分期、组织病理类型、ＰＲ受体以及５年生存率无关；与细胞分级有关，低分化内膜癌Ｐｇｐ强阳性较中、高分化内膜癌Ｐｇｐ强阳性表达高，二者差异有统计学意义。结论：子宫内膜癌患者对抗肿瘤药具有先天性抗药性，Ｐｇｐ表达是子宫内膜癌化疗疗效不佳的原因之一。

S tudy on the detection of multidrug resistance 1 gene product P-gp in endometrial carcinomas and its clinical significance

Objective: To study the clinical significance of P gp expression in endometrial carcinoma. Methods: The expression of P gp on paraffin section in 40 cases of endometrial carcinoma, 10 of endometrial neoplasia and 10 of normal endometrium were detected by SP immunohistochemical methods. Results: The expression of P gp was found in all tissues mentioned above. The strongly positive staining in the endometrial carcinoma was significantly higher than that of the normal endometrium and associated with carcinoma cell grades, not associated with clinical prognostic factors. Conclusion: That there are primary multidrug resistance for endometrial carcinoma which may be one of the reasons for chemotherapy failure.